Details for Patent: 9,074,256
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,074,256 protect, and when does it expire?
Patent 9,074,256 protects FANAPT and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 9,074,256
Title: | Method of predicting a predisposition to QT prolongation |
Abstract: | The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation. |
Inventor(s): | Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Potomac, MD) |
Assignee: | Vanda Pharmaceuticals, Inc. (Washington, DC) |
Application Number: | 13/263,076 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,074,256 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,074,256
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-001 | May 6, 2009 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-002 | May 6, 2009 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
Vanda Pharms Inc | FANAPT | iloperidone | TABLET;ORAL | 022192-003 | May 6, 2009 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,074,256
PCT Information | |||
PCT Filed | April 05, 2010 | PCT Application Number: | PCT/US2010/029943 |
PCT Publication Date: | October 14, 2010 | PCT Publication Number: | WO2010/117941 |
International Family Members for US Patent 9,074,256
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Canada | 2757723 | See Plans and Pricing | |||
European Patent Office | 2416778 | See Plans and Pricing | |||
Japan | 2012522534 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |